VM:CA:TSV-Voyageur Pharmaceuticals Ltd (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.065

Change

-0.01 (-7.14)%

Market Cap

USD 9.76M

Volume

0.12M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in the acquiring, exploring, and developing raw materials for pharmaceutical products in the province of British Columbia, Canada, and the state of Utah. It develops barium, iodine-based APIs, and imaging contrast agents for medical radiology. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. is headquartered in Calgary, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-15 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
RX:CA Biosyent Inc.

+0.05 (+0.45%)

USD 0.13B
LOVE:CA Cannara Biotech Inc

+0.01 (+1.67%)

USD 0.07B
ZYUS:CA ZYUS Life Sciences Corporation

N/A

USD 0.06B
SBBC:CA Simply Better Brands Corp

+0.04 (+6.35%)

USD 0.06B
LSL:CA LSL Pharma Group Inc.

+0.02 (+3.45%)

USD 0.05B
HASH:CA Simply Solventless Concentrate..

-0.01 (-1.75%)

USD 0.05B
DB:CA Decibel Cannabis Company Inc

-0.01 (-7.14%)

USD 0.03B
ROMJ:CA Rubicon Organics Inc

-0.02 (-3.80%)

USD 0.02B
PCLO:CA Pharmacielo Ltd

N/A

USD 0.02B
ELXR:CA Elixxer Ltd

N/A

USD 0.01B

ETFs Containing VM:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.33% 56% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.33% 56% F 55% F
Trailing 12 Months  
Capital Gain 44.44% 89% A- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.44% 89% A- 79% B-
Trailing 5 Years  
Capital Gain -7.14% 78% C+ 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.14% 78% C+ 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 9.66% 74% C 60% D-
Dividend Return 9.66% 74% C 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 59.71% 42% F 45% F
Risk Adjusted Return 16.18% 84% B 63% D
Market Capitalization 9.76M 50% F 57% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector